Thanks! You've successfully subscribed to the BONEZONE®/OMTEC® Monthly eNewsletter!

Please take a moment to tell us more about yourself and help us keep unwanted emails out of your inbox.

Choose one or more mailing lists:
BONEZONE/OMTEC Monthly eNewsletter
OMTEC Conference Updates
Advertising/Sponsorship Opportunities
Exhibiting Opportunities
* Indicates a required field.

Materials Rapid-Fire

Orthopaedic innovation is linked to the adoption of new materials. This rapid-fire session will profile the properties and orthopaedic indications of emerging materials. Each presenter will have 20 minutes to speak, to be followed by a Q&A with all three speakers. Matt Poggie, Vice President of R&D, Acuitive Technologies and previous Senior Director of Applied Technology at Stryker, will moderate this session.

Silicon Nitride
Bryan McEntire, Chief Technology Officer, AMEDICA
Bryan McEntire WebSilicon Nitride (Si3N4) has a distinctive set of material properties, such as high strength and fracture toughness, inherent phase stability, low wear, scratch resistance, biocompatibility, hydrophilicity, excellent radiographic imaging and bacterial resistance. These attributes make it an excellent candidate for demanding structural implants in various orthopaedic applications. It is currently used in spinal fusion cages, and is being considered as a bearing surface in total hip or knee arthroplasty. Si3N4 is a non-oxide ceramic in its bulk, but possesses a protective Si-N-O transitional layer at its surface. Unlike oxide ceramics, the surface chemistry and topography of Si3N4 can be uniquely modified or modulated to address potential in vivo needs. Morphologically, it can be manufactured to have an ultra-smooth or highly fibrous surface structure. Its chemistry can be varied from that of a silica-like surface to one that is predominately silicon-amine-based. Various common mechanical or chemical methods can be used to engineer these modifications.

Mr. McEntire is Chief Technology Officer of AMEDICA and has 40 years of industrial experience in the research, development and manufacturing of advanced ceramics. Prior to joining AMEDICA, Mr. McEntire served as a Senior Director of Supply Chain Management at Applied Materials. He holds BS and MBA degrees in Materials Science and Engineering and Operations Management, respectively, both from the University of Utah. He is an author or co-author of over 45 technical papers on ceramic materials, processing and characterization.


BioMg®

Stephen LeBeau, President and Technical Director, nanoMAG
Steve LeBeau webPatients who break a bone face a lifelong future with metal implants that may limit the range of motion or cause other problems, such as stress points that could lead to another fracture; patients may also elect to undergo a second surgery to remove the devices. For pediatric patients who may outgrow their implants, the only option is a secondary surgery. A solution to these problems is biocompatible, bioabsorbable magnesium alloy implants that are strong enough to support the bone during healing, but degrade over time while providing nutrients to promote bone regrowth. Recent in vivo testing histology examinations after 52 weeks exhibit evidence of bone structures in intimate contact with the surface of the Mg implants, indicating that the magnesium implants are not only biocompatible, but in fact can serve as a catalyst for the promotion of new bone structures around the implants while they are being absorbed. OEM partners have been engaged for medical indications ranging from knee and shoulder anchors to cranial facial repair and coronary stents.

Dr. LeBeau, President and Technical Director of nanoMAG, has spent his entire 35+ year career in the areas of manufacturing and materials processing development. The first 15 years of his career were spent at Fortune 500 companies, followed by a transition to privately-held venture startup companies focused on commercialization of new materials manufacturing technologies. nanoMAG LLC is the third startup company at which Dr. LeBeau has played a critical role in implementation and achieving commercial success.

 
Proxy Bio-XT
Niall Rooney, Director of Business Development, Proxy Biomedical

Niall Rooney webProxy Bio-XT is a processing technology that optimizes the microstructure of biomaterials to enable greater than 100 percent strength gain in resorbable implants. The strength gain afforded by Bio-XT processing technology provides a platform for the development of a new generation of resorbable orthopaedic implants. The higher strength achieved affords the possibility to explore new indications or to offset this strength gain for thinner or more porous designs. Proxy Bio-XT can be applied to any resorbable polymer or biocomposite blends, enabling new designs to leverage the same resorbable grades as those used in current products.

Niall Rooney BE Ph.D. holds the position of Director of Business Development at Proxy Biomedical, located in Galway, Ireland. Dr. Rooney has been with the company since 2009. Qualified with a Bachelor’s Degree in Mechanical Engineering and a Ph.D. in Orthopaedic Implant Design, both from UCD Dublin, Dr. Rooney has overseen the transition of Bio-XT processing technology from engineering development through to commercial realization.

 

Session Takeaways:
 ● How new materials are advancing orthopaedic devices

Who Should Attend? 

  ● Materials/Commodity Management 
  ● Research & Development
  ● Regulatory/Clinical Affairs

Prepare for this session with these materials resources:
Materials a Major Driver in Implant Innovation
Choosing Materials in a Shifting Global Regulatory Environment
Supplier Roundtable: Materials Suppliers